Abbott Laboratories Stock

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q1 2024 Earnings CallApr 17, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Dividend-paying stocks have generally outperformed those that don't pay dividends over the long term. That's partly because maintaining a healthy dividend requires a solid underlying business. And

Anti-obesity drugs rose in popularity last year, helping the leaders in this market -- notably Eli Lilly and Novo Nordisk -- crush the market. However, some medical device specialists got the wrong

Abbott Laboratories (NYSE: ABT) has proven itself as a long-term winner for investors. The healthcare giant has grown earnings over time, and the shares have climbed too. In just the past year

When is it time to buy a stock? One of the best-known pieces of investing advice tells us to buy low and sell high. But what constitutes "low" is relative. A stock near its 52-week high can still be

Dividend Kings are unquestionably among the top picks for income-seeking investors. These are companies that have increased their payouts for at least 50 consecutive years, which strongly suggests

Abbott Laboratories (NYSE: ABT) is a diversified health care company that gives investors a great deal of stability. Between testing, nutritional products, pharmaceuticals, and medical devices, the

Drugmakers Novo Nordisk and Eli Lilly have been making headlines in recent times, thanks to their sought-after weight loss drugs. In fact, the products have become so popular that demand has

As you build your portfolio through the years, you may find that you gravitate toward stocks across an assortment of sectors, with a range of risk profiles, growth stories, and businesses

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q4 2023 Earnings CallJan 24, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

Abbott Laboratories (NYSE: ABT) is a longtime leader in the healthcare industry. The medical device specialist has been around for decades, delivering solid returns to its loyal shareholders

Drugmaker AbbVie (NYSE: ABBV) spun off from Abbott Laboratories (NYSE: ABT) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue

As the year draws to a close, it's as good a time as any to review one's investments and consider adding more money into the stock market. The goal shouldn't be to take advantage of the January

The past three years have been a roller coaster for Abbott Laboratories (NYSE: ABT). The healthcare giant dealt with a slowdown in its medical device business caused by the pandemic, fluctuating